Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

Bernhard Kreymann, Mohammad A. Ghatei, Gareth Williams et al. · The Lancet · 1987 · 1.9K citations

Life Sciences, Endocrinology, Physiology +10

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

Mette Zander, Sten Madsbad, Jan Lysgaard Madsen et al. · The Lancet · 2002 · 1.3K citations

Medicine, Endocrinology, Internal Medicine +16

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Michael A. Nauck, N. Kleine, C. �rskov et al. · Diabetologia · 1993 · 1.1K citations · Full text

Medicine, Endocrinology, Internal Medicine +15

(2<i>R</i>)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-<i>a</i>]pyrazin- 7(8<i>H</i>)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine:  A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15